clinical trial · NCT05601752
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
USWM CT, LLC·phase2·active not recruiting·n = 66
Ovarian CancerAutologous genetically modified ADP-A2M4CD8 cellsAutologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
brief summary
This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.
started
Jun 26, 2023
primary completion
Aug 12, 2026
completion
Aug 12, 2026
last updated
Aug 12, 2026
official title
A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol